GYRE
Gyre Therapeutics Inc
$
8.210
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.225
Open
7.540
VWAP
8.00
Vol
105.50K
Mkt Cap
745.69M
Low
7.4069
Amount
844.39K
EV/EBITDA(TTM)
58.63
Total Shares
90.83M
EV
669.70M
EV/OCF(TTM)
722.44
P/S(TTM)
7.27
Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
Show More
4 Analyst Rating
195.37% Upside
Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 24.25 USD with a low forecast of 20.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
195.37% Upside
Current: 8.210
Low
20.00
Averages
24.25
High
28.00
195.37% Upside
Current: 8.210
Low
20.00
Averages
24.25
High
28.00
The End
See All Ratings
No Data
Valuation Metrics
The current forward P/E ratio for Gyre Therapeutics Inc (GYRE.O) is 0.00, compared to its 5-year average forward P/E of 5.98. For a more detailed relative valuation and DCF analysis to assess Gyre Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
5.98
Current PE
0.00
Overvalued PE
26.04
Undervalued PE
-14.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.59
Current PS
0.00
Overvalued PS
2.51
Undervalued PS
-1.34
Financials
Annual
Quarterly
FY2025Q2
YoY :
+6.13%
26.77M
Total Revenue
FY2025Q2
YoY :
-33.45%
2.17M
Operating Profit
FY2025Q2
YoY :
-65.27%
1.58M
Net Income after Tax
FY2025Q2
YoY :
-100.00%
0.00
EPS - Diluted
FY2025Q2
YoY :
-126.03%
1.81M
Free Cash Flow
FY2025Q2
YoY :
-1.29%
95.70
Gross Profit Margin - %
FY2025Q2
YoY :
-112.08%
-1.58
FCF Margin - %
FY2025Q2
YoY :
-67.26%
5.89
Net Margin - %
FY2025Q2
3.74
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
496.3K
USD
27
6-9
Months
1.0M
USD
48
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
496.3K
USD
27
6-9
Months
1.0M
USD
48
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GYRE News & Events
Events Timeline
2025-08-11 (ET)
2025-08-11
16:03:58
Gyre Therapeutics CEO Han Ying steps down
2025-06-10 (ET)
2025-06-10
07:08:05
Gyre Therapeutics announces first doing in Phase 1 trial of F230
2025-05-22 (ET)
2025-05-22
23:55:59
Gyre Therapeutics 2.22M share Spot Secondary priced at $9.00
Sign Up For More Events
Sign Up For More Events
News
9.0
06-10NewsfilterGyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
2.0
05-27BenzingaMAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday
2.0
05-23BenzingaRoss Stores, Deckers Outdoor, Xerox Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Sign Up For More News
People Also Watch
PARR
Par Pacific Holdings Inc
28.820
USD
+2.42%
FIGS
Figs Inc
6.960
USD
+4.98%
BBDC
Barings BDC Inc
9.710
USD
+0.41%
SKE
Skeena Resources Ltd
15.780
USD
-0.19%
TPB
Turning Point Brands Inc
99.840
USD
+0.87%
OPK
OPKO Health Inc
1.350
USD
+2.27%
CSR
Centerspace
56.020
USD
+1.71%
DCO
Ducommun Inc
92.360
USD
-0.19%
HEPS
D Market Elektronik Hizmetler ve Ticaret AS
3.000
USD
-1.64%
ADPT
Adaptive Biotechnologies Corp
13.000
USD
+2.69%
FAQ
What is Gyre Therapeutics Inc (GYRE) stock price today?
The current price of GYRE is 8.21 USD — it has increased 8.6 % in the last trading day.
What is Gyre Therapeutics Inc (GYRE)'s business?
What is the price predicton of GYRE Stock?
What is Gyre Therapeutics Inc (GYRE)'s revenue for the last quarter?
What is Gyre Therapeutics Inc (GYRE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Gyre Therapeutics Inc (GYRE)'s fundamentals?
How many employees does Gyre Therapeutics Inc (GYRE). have?